Validated instruments measure current disease burden in chronic spontaneous urticaria rather than long term prognosis
New Tools Help Doctors Track Chronic Urticaria and Angioedema
This guideline provides a narrative review of scoring systems and biomarkers for risk stratification in chronic spontaneous urticaria. The r…
New scoring systems and biomarkers help doctors better track disease activity and identify which patients might respond best to specific tre…
Limited evidence exists for biomarkers in diagnosing or monitoring chronic inducible urticaria
New research looks at ways to better track and treat skin allergies
This scoping review of 42 studies maps the current evidence for biomarkers in chronic inducible urticaria. While some exploratory associatio…
Doctors are looking for better ways to test and treat skin reactions caused by cold, sweat, or pressure.
Elevated eosinophil counts correlate with increased odds of SNOT-22 improvement in CRSwNP patients
High Eosinophil Counts Linked to Better Treatment for Nasal Polyps
This meta-analysis of 489 adults with CRSwNP found that patients with elevated eosinophils (>300 cells/µL) had increased odds of SNOT-22 imp…
Patients with high eosinophil counts may see better symptom relief from specific treatments for chronic rhinosinusitis with nasal polyps.
Biologics provide effective and long-lasting disease control for chronic rhinosinusitis with nasal polyps
Biologics May Help Chronic Sinusitis With Nasal Polyps
This narrative review examines the efficacy of biologics, including dupilumab, mepolizumab, omalizumab, and tezepelumab, for patients with c…
A new review suggests biologic drugs may improve sinus symptoms, smell, and asthma in people with nasal polyps.
Depemokimab shows no significant difference from other biologics in reducing severe asthma exacerbations
Depemokimab Shows Similar Results to Other Biologics for Severe Asthma
This systematic review and indirect treatment comparison evaluated depemokimab against omalizumab, benralizumab, dupilumab, and placebo in p…
A new review finds that the drug depemokimab performs similarly to other established biologics in reducing severe asthma flare-ups.
Therapeutic advances in IgE-mediated food allergy lack validated risk-stratification tools for individualized care
Newer treatments for food allergies lack clear safety tools
This mini review synthesizes therapeutic innovations for IgE-mediated food allergy, including oral immunotherapy, omalizumab, and combinatio…
Doctors are looking for better ways to manage food allergies, but they currently lack validated tools to help decide which specific treatmen…
Biologic-assisted immunotherapy including omalizumab and dupilumab may support oral and sublingual immunotherapy for pediatric food allergies
New review explores biologic drugs for food allergy in children
This systematic review examines the efficacy, safety, and clinical applicability of biologic-assisted immunotherapies, such as omalizumab an…
A systematic review looks at whether adding biologic drugs like omalizumab to immunotherapy helps kids with food allergies.
Omalizumab may improve asthma and food allergy in a pediatric liver transplant recipient
Omalizumab helps teen with food allergy after liver transplant
A narrative review of a case report describes a 15-year-old boy with a liver transplant and de novo post-transplant food allergy who receive…
A 15-year-old with a liver transplant and severe food allergies improved with omalizumab, gaining asthma control and a less restricted diet.
Switching Biologics in Severe Asthma Patients Shows Improved Clinical Outcomes and Reduced Exacerbations Across Multiple Therapies
Switching Asthma Drugs Could Change Your Life
A systematic review and meta-analysis of 2,292 patients found that switching biologics significantly reduced exacerbations and improved asth…
If your severe asthma medication stops working, switching to a different biologic drug could cut your attacks in half and help you breathe e…
Narrative review highlights mechanistic gaps and limited efficacy in chronic inducible urticaria treatment options
New Hope for Chronic Hives Targets Specific Triggers
This narrative review examines chronic inducible urticaria (CIndU), focusing on H1-antihistamines, omalizumab, anti-KIT biologics, and BTK i…
New medicines are being built to fix the exact reason your hives appear, moving away from a one-size-fits-all approach.
Retrospective case series evaluates omalizumab efficacy in Chinese pediatric chronic spontaneous urticaria patients
This Hives Medicine Might Help Young Children Finally Find Relief
This retrospective case series assessed omalizumab in 13 Chinese children under 12 years with chronic spontaneous urticaria.
A common hives drug shows promise for younger kids who usually have few options.
Machine learning model predicts omalizumab efficacy duration in moderate-to-severe perennial allergic rhinitis patients
A smart model that predicts how long your allergy shot will last
This retrospective cohort study evaluated predictors of omalizumab efficacy duration in 561 patients with moderate-to-severe perennial aller…
A new computer model can estimate how long a popular allergy shot will keep working for each person, making treatment more personal.